Pharmacyte Biotech Inc (OTCMKTS:PMCB) is a biotechnology company that focuses in the manufacture of medical products targeting diabetes and cancer. The company says that the final pre-production run of pancreatic cancer is already complete.
A close outlook
Austrianova and Pharmacyte Biotech are long-term partners. The company has applauded Austrianova for the big role it played towards the completion of the final pre-production run of pancreatic cancer.
The company combines the new product with low doses of the cancer prodrug ifosfamide. Experts say the combination is quite effective in the treatment of advanced inoperable pancreatic cancer (LAPC).
PharmaCyte’s Chief Scientific Officer and Austrianova will oversee PharmaCyte’s clinical trial material full production process.
PharmaCyte’s CEO Kenneth L. Waggoner said, “We are happy to report that the encapsulation portion of the process during the pre-production run went flawlessly. Our decision has proven to be the correct course of action.”
Waggoner outlined that the company’s decision was appropriate since it was the correct course of action. The company understands exactly how the cells from the Master Cell Bank (MCB) function in the course of the encapsulation and thereafter.
The turn of events
Austrianova made several changes to the cell culture portion of the entire production mechanism. The company hopes to submit its IND to the FDA in good time but before that it must complete the full production process. The testing of the final product is also happens beforehand.
The two engineering runs involved were a source or great knowledge. The company is currently eyeing the final production run where it will engage in the production of clinical trial material. Austrianova said that the entire production process did not take much of its time.
So far it has managed to fill quite a significant number of syringes with capsules produced in the course of the pre-production run. The process almost resembles what will take place in the final production run.
PharmaCyte says that it was a great moment for it to undertake another study on encapsulated cells successfully. Cancer patients hope that the company will consider the best strategies in developing top-notch solutions to help them.